Atlas Trials

A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

Clinical trial NCT03505554 · COMPLETED

Trial details

NCT number
NCT03505554
Sponsor
University of Milano Bicocca
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Anaplastic Large Cell Lymphoma, ALK-Positive
Start date
2019-09-28
Primary completion
2025-12-31
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.